News on Daiichi Sankyo%2C Inc. from BioPortfolio.com http://www.BioPortfolio.com Consolidated Daiichi Sankyo%2C Inc. news from BioPortfolio.com Wed, 10 Feb 2010 01:53:31 GMT en Daiichi Sankyo files Japanese new drug application for Alzheimer's drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035977&HITNO=0&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035977&THISHREF=http://c.moreover.com/click/here.pl%3fz2536439329%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035977&HITNO=0&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035977&THISHREF=http://c.moreover.com/click/here.pl%3fz2536439329%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: Daiichi Sankyo files Japanese new drug application for Alzheimer's drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035111&HITNO=1&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035111&THISHREF=http://c.moreover.com/click/here.pl%3fz2536119166%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035111&HITNO=1&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035111&THISHREF=http://c.moreover.com/click/here.pl%3fz2536119166%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTradingMarkets: Daiichi initiates phase III trial of thromboembolism drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4027632&HITNO=2&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4027632&THISHREF=http://c.moreover.com/click/here.pl%3fz2532265111%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4027632&HITNO=2&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4027632&THISHREF=http://c.moreover.com/click/here.pl%3fz2532265111%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBio Spectrum Asia: ArQule initiates two cancer studieshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030344&HITNO=3&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030344&THISHREF=http://c.moreover.com/click/here.pl%3fz2533577553%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030344&HITNO=3&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030344&THISHREF=http://c.moreover.com/click/here.pl%3fz2533577553%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comDatamonitor: ArQule Announces Initiation Of Clinical Programs With ARQ 197 In Germ Cell Tumors And Colorectal Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026573&HITNO=4&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026573&THISHREF=http://c.moreover.com/click/here.pl%3fz2530978589%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026573&HITNO=4&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026573&THISHREF=http://c.moreover.com/click/here.pl%3fz2530978589%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: Exelixis Announces February 9 Webcast of Presentation at the 12th Annual BioCEO and Investor Conferencehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026259&HITNO=5&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026259&THISHREF=http://c.moreover.com/click/here.pl%3fz2530548476%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026259&HITNO=5&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026259&THISHREF=http://c.moreover.com/click/here.pl%3fz2530548476%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Daiichi Sankyo: new influenza drug may boost flagging Japanese markethttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026833&HITNO=6&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026833&THISHREF=http://c.moreover.com/click/here.pl%3fz2531375807%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026833&HITNO=6&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026833&THISHREF=http://c.moreover.com/click/here.pl%3fz2531375807%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPipelineReview: Thought Leader Panel Assesses Anticoagulants Market in New MedPredict Reporthttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026707&HITNO=7&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026707&THISHREF=http://c.moreover.com/click/here.pl%3fz2531200044%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026707&HITNO=7&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026707&THISHREF=http://c.moreover.com/click/here.pl%3fz2531200044%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPRWeb: ArQule initiates two cancer studieshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023928&HITNO=8&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023928&THISHREF=http://c.moreover.com/click/here.pl%3fz2528489678%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023928&HITNO=8&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023928&THISHREF=http://c.moreover.com/click/here.pl%3fz2528489678%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Preventiohttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024545&HITNO=9&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024545&THISHREF=http://c.moreover.com/click/here.pl%3fz2528985349%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024545&HITNO=9&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024545&THISHREF=http://c.moreover.com/click/here.pl%3fz2528985349%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Unhappy FDA tells Ranbaxy to review unitshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4025364&HITNO=10&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4025364&THISHREF=http://c.moreover.com/click/here.pl%3fz2529702885%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4025364&HITNO=10&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4025364&THISHREF=http://c.moreover.com/click/here.pl%3fz2529702885%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comRBC Dain Rauscher: Ranbaxy again falls foul of US FDA, which calls for new plant assessmenthttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024600&HITNO=11&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024600&THISHREF=http://c.moreover.com/click/here.pl%3fz2529006351%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024600&HITNO=11&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024600&THISHREF=http://c.moreover.com/click/here.pl%3fz2529006351%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Letter: ArQule Announces Initiation of Clinical Programs with ARQ 197 in Germ Cell Tumors and Colorectal Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018207&HITNO=12&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018207&THISHREF=http://c.moreover.com/click/here.pl%3fz2525525471%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018207&HITNO=12&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018207&THISHREF=http://c.moreover.com/click/here.pl%3fz2525525471%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: ArQule Announces Initiation of Clinical Programs with ARQ 197 in Germ Cell Tumors and Colorectal Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018057&HITNO=13&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018057&THISHREF=http://c.moreover.com/click/here.pl%3fz2525450740%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018057&HITNO=13&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018057&THISHREF=http://c.moreover.com/click/here.pl%3fz2525450740%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Exelixis Announces February 9 Webcast of Presentation at the 12th Annual BioCEO and Investor Conferencehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023324&HITNO=14&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023324&THISHREF=http://c.moreover.com/click/here.pl%3fz2528160964%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023324&HITNO=14&MSIZE=398&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Daiichi%20Sankyo,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023324&THISHREF=http://c.moreover.com/click/here.pl%3fz2528160964%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: